Paul Knöbl
Medical University of Vienna
Internal medicineEndocrinologySurgeryAutoantibodyChemistryImmunologyChemotherapyCoagulationLeukemiaThrombotic thrombocytopenic purpuraVon Willebrand factorImmunoadsorptionCoagulopathyADAMTS13Protein CIn patientAnesthesiaMedicinePlateletGastroenterology
172Publications
52H-index
5,150Citations
Publications 173
Newest
#1Paul Knöbl (Medical University of Vienna)H-Index: 52
#2Rüdiger E Scharf (Boston Children's Hospital)
Source
#1Nina Buchtele (Medical University of Vienna)H-Index: 7
#2Michael SchwameisH-Index: 21
Last. Bernd JilmaH-Index: 70
view all 11 authors...
OBJECTIVES Extracorporeal membrane oxygenation provides large surface exposure to human blood leading to coagulation activation. Only limited clinical data are available on contact activation and coagulation factor XII activity in extracorporeal membrane oxygenation patients. DESIGN Prospective cohort study. SETTING Three medical ICUs at the Medical University of Vienna. PATIENTS Adult patients receiving venovenous or venoarterial extracorporeal membrane oxygenation. INTERVENTIONS None. MEASUREM...
Source
#1Johannes Thaler (Medical University of Vienna)H-Index: 23
#2Cihan Ay (Medical University of Vienna)H-Index: 48
Last. Paul Knöbl (Medical University of Vienna)H-Index: 52
view all 9 authors...
Cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV-19 vaccine (AstraZeneca) have been reported. The term vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) was coined to reflect this new phenomenon. In vitro experiments with VIPIT patient sera indicated that high dose intravenous immunoglobulins (IVIG) competitively inhibit the platelet activating properties of ChAdOx1 nCoV-19 vaccine induced antibodies. Here, we report a case of a 62-year-old wo...
34 CitationsSource
#1Erika Tarasco (University of Bern)H-Index: 1
#2Lukas BütikoferH-Index: 17
Last. Johanna A. Kremer Hovinga (University of Bern)H-Index: 40
view all 18 authors...
Abstract Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare thrombotic microangiopathy characterized by severe congenital ADAMTS13 deficiency and recurring acute episodes causing morbidity and premature death.Information on the annual incidence and severity of acute episodes in hTTP patients is largely lacking. This study reports prospective data of 87 patients from the Hereditary TTP Registry ( ClinicalTrials.gov NCT01257269 ) for survival, frequencyand severity of acute episodesfr...
4 CitationsSource
#1Johannes Gratz (Medical University of Vienna)H-Index: 5
#2Marion Wiegele (Medical University of Vienna)H-Index: 6
Last. Eva Schaden (Medical University of Vienna)H-Index: 15
view all 8 authors...
Background: Early during the course of the ongoing COVID-19 pandemic, reports suggested alarmingly high incidences for thromboembolic events in critically ill patients with COVID-19. However, the clinical relevance of these events was not reported in several studies. Additionally, more recent research showed contradictory results and suggested substantially lower rates of venous thromboembolism. Thus, the aim of the present study was to summarize evidence on the incidence of clinically relevant ...
3 CitationsSource
#1Andreas Tiede (MHH: Hannover Medical School)H-Index: 30
#2Bettina Kemkes-Matthes (University of Giessen)H-Index: 17
Last. Paul Knöbl (Medical University of Vienna)H-Index: 52
view all 3 authors...
Emicizumab is currently approved to prevent bleeding in patients with congenital hemophilia A with or without neutralizing antibodies (inhibitors) against factor VIII (FVIII). Here, we present a case-based discussion of its potential use in acquired hemophilia A (AHA), a severe bleeding disorder caused by autoantibodies against FVIII. State-of-the-art management is based on bypassing agents (recombinant factor VIIa, activated prothrombin complex concentrate) and recombinant porcine FVIII; immuno...
6 CitationsSource
BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Current standard of care is therapeutic plasma exchange, immunosuppression, and caplacizumab, an anti-von Willebrand Factor Nanobody, which is effective in treating aTTP episodes. PATIENTS/METHODS Here we report on 7 episodes of aTTP treated without plasma exchange in 6 female patients in Germany and Austria. Two episodes were initial presentations of aTTP, in 5 insta...
13 CitationsSource
#1Hendrika Anette van Dorland (University of Bern)H-Index: 3
#2Magnus Mansouri Taleghani (University of Bern)H-Index: 4
Last. Isabella Aebi-Huber (University of Bern)H-Index: 2
view all 22 authors...
1 CitationsSource
#1Katharina Holstein (UHH: University of Hamburg)H-Index: 11
#2Xiaofei Liu (MHH: Hannover Medical School)H-Index: 2
Last. Andreas Tiede (MHH: Hannover Medical School)H-Index: 30
view all 9 authors...
Acquired hemophilia A (AHA) is due to autoantibodies against coagulation factor VIII (FVIII) and most often presents with unexpected bleeding. In contrast to congenital hemophilia, the patient's residual FVIII activity does not seem to correlate with the risk of bleeding as suggested from previous studies. Risk factors for bleeding have not been described. We used data from the prospective GTH-AH 01/2010 study to assess the risk of bleeding and the efficacy of hemostatic therapy. FVIII activity ...
12 CitationsSource
#1Klaus GeisslerH-Index: 41
#2Eva Jäger (Medical University of Vienna)H-Index: 6
Last. Peter Valent (Medical University of Vienna)H-Index: 130
view all 32 authors...
Although the RAS-pathway has been implicated as an important driver in the pathogenesis of chronic myelomonocytic leukemia (CMML) a comprehensive study including molecular and functional analyses in patients with progression and transformation has not been performed. A close correlation between RASopathy gene mutations and spontaneous in vitro myeloid colony (CFU-GM) growth in CMML has been described. Molecular and/or functional analyses were performed in three cohorts of 337 CMML patients: in p...
6 CitationsSource